Chengdu Zelynx Biotech's Hong Kong IPO Prospectus Expires After 6-Month Validity Period

According to ZhiTong Finance, Chengdu Zelynx Biotech's Hong Kong IPO prospectus, submitted on January 13, 2026, expired on July 13, 2026, after reaching its six-month validity limit. Jefferies and CICC served as joint sponsors.

Zelynx Biotech is a late-stage clinical biotechnology company developing differentiated small-molecule therapeutics for blood disorders, oncology, central nervous system, and immune/inflammatory diseases. As of January 5, 2026, the company's pipeline comprises two core candidates in Phase 3 registration trials, two additional clinical-stage candidates, and four preclinical-stage candidates.